Prefusion glycoprotein F0/pre-F protein (NiV)

Prefusion glycoprotein F0/pre-F protein (NiV) Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Nipah virus (1)

  • Tag

    His Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
FUN-N52H3
Nipah virus
HEK293
Nipah virus Pre-Fusion glycoprotein, His Tag (MALS verified)
Total: 1
  • 1

Prefusion glycoprotein F0/pre-F protein (NiV) Background

Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Retroviral vector-transduced autologous T cells to express anti-ALPP CARs (TCRCure Biopharma Corporation)Phase 2 ClinicalXinqiao Hospital, Army Medical UniversityOvarian Neoplasms; Endometrial Neoplasms
Details
  • Product List
  • Clinical Drug Information